Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw some unusual options trading activity on Thursday. Traders acquired 12,612 call options on the stock. This represents an increase of approximately 235% compared to the typical volume of 3,762 call options.

Analysts Set New Price Targets

OMER has been the subject of a number of research reports. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Key Stories Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Significant earnings and revenue beats: Omeros reported second-quarter earnings of $0.02 per share, versus analysts’ expected loss of $0.27 per share and a $0.53 loss a year earlier. Revenue reached $28.53 million, more than double the $12.69 million consensus estimate. The results improved investor confidence in the company’s commercial performance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: YARTEMLEA momentum is supporting the outlook: Management highlighted strong early demand for YARTEMLEA, which is becoming an important commercial growth driver. Analysts also cited reduced competition in the C5 market as a positive factor for the product’s potential. Omeros Earnings Call: Yartemlia Surge and Leaner Balance Sheet
• Positive Sentiment: Balance-sheet and shareholder actions added to the catalyst: The earnings update emphasized debt reduction and a leaner balance sheet, while share repurchases provided an additional potential source of per-share support. OMER Stock Soars After YARTEMLEA Sales Momentum, Debt Reduction and Share Buybacks
• Positive Sentiment: Analyst remains bullish: H.C. Wainwright reiterated its Buy rating and maintained a $33 price target, citing YARTEMLEA’s launch trajectory and reduced C5 competition. This target is well above the stock’s recent trading range and reinforces the bullish reaction to the results. Omeros Maintained at Buy With $33 Price Target
• Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful short-squeeze or bearish-positioning signal.

Omeros Stock Up 23.2%

Shares of Omeros stock traded up $3.19 during midday trading on Thursday, hitting $16.90. The company’s stock had a trading volume of 6,079,697 shares, compared to its average volume of 1,637,689. The firm has a market capitalization of $1.22 billion, a P/E ratio of 24.12 and a beta of 2.54. The stock has a 50-day simple moving average of $10.60 and a 200-day simple moving average of $11.47. Omeros has a 1-year low of $3.94 and a 1-year high of $18.14.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. As a group, sell-side analysts predict that Omeros will post -0.94 earnings per share for the current year.

Insider Activity

In other news, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director owned 35,067 shares of the company’s stock, valued at $407,127.87. The trade was a 17.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omeros

Institutional investors have recently modified their holdings of the stock. State of Wyoming purchased a new stake in shares of Omeros during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Omeros in the fourth quarter valued at about $33,000. Assetmark Inc. acquired a new position in Omeros in the 1st quarter worth about $38,000. Arax Advisory Partners increased its position in Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,894 shares during the last quarter. Finally, International Assets Investment Management LLC increased its position in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.